INS and metabolic syndrome: Likewise, mixed outcomes are also reported in individuals with metabolic syndrome; while Méndez del Villar et al. [44] reported a decreased insulin response to glucose and total insulin secretion without affecting glucose levels, Kjœr et al. [43] reported no beneficial effects and actually found an increase in circulating fructosamine levels.